Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony czerniak z przerzutami, który nie może być operacyjnie usunięty (stopień III-IV)
- •Czerniak nie reagował na wcześniejsze leczenie immunoterapią (leki anty-PD1/L1) lub pogorszył się podczas tego leczenia
- •Pacjent otrzymał co najmniej 2 dawki leczenia immunoterapią, a choroba dalej się pogarsza
- •Pogorszenie choroby potwierdzone badaniami obrazowymi wykonanymi w ciągu 12 tygodni od ostatniego leczenia
- •Pisemna zgoda pacjenta na udział w badaniu
✗ Disqualifies
- •Symptomatyczne zmiany nowotworowe w mózgu lub szybko rosnące zmiany mózgowe z krwawieniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Hartford Hospital
Hartford, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Universitätsklinikum Essen
Essen, Germany
University of Freiburg, Faculty of Medicine
Freiburg im Breisgau, Germany
University Hospital Schleswig-Holstein
Kiel, Germany
University Hospital Tuebingen
Tübingen, Germany
IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale"
Naples, Italy
Trial contact
Sheila Dakhel Plaza, PhD
Concetta Aulicino
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.